Monica E. Luchi - 05 May 2022 Form 4 Insider Report for Brickell Biotech, Inc.

Reporting relationship: Chief Medical Officer
Issuer ticker: N/A
Reported as of: 05 May 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 May 2022, 16:16:12 UTC
Prior SEC filing: 03 Sep 2021
Source filing: View source filing
Reporting owner signature: /s/ Christine G. Long, Attorney-in-Fact for Monica Luchi (power of attorney previously filed)

Key filing fact

Monica E. Luchi filed Form 4 for Brickell Biotech, Inc. on 09 May 2022.

Key facts

This page summarizes Monica E. Luchi's Form 4 filing for Brickell Biotech, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 09 May 2022, 16:16.

Change

Previous filing in this sequence was filed on 03 Sep 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FRTX transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +325,000
Change %
Price: $0.000000
Shares after: 325,000
Date: 05 May 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 325,000
Exercise price: $0.2600
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock options will vest 25% on the first anniversary of the grant date, and the remainder will vest in equal monthly installments over the following three years.